<!-- http://cnnfn.cnn.com/2001/06/22/markets/markets_newyork/ -->

Dow industrials catch cold
 
Drug stocks take a dive, but the market ends the week little changed
 
By Staff Writer Jake Ulick
June 22, 2001: 4:28 p.m. ET
 
NEW YORK (CNNfn) - The Dow Jones industrial average tumbled Friday after one of the market's most dependable sectors, drug companies, succumbed to the profit worries that have hammered technology shares all year.

Merck fell as much as 9.1 percent when the company became the latest to warn that earnings would miss forecasts. Rival Schering-Plough, meanwhile, said U.S. regulators found deficiencies in its plants, sending its shares down as much as 9.6 percent.

"If you can't hide in drugs, where can you hide?" asked Paul McManus, portfolio manager of the John Hancock Core Equity Fund. "Drug stocks have been dependable, a good defensive play, a good place to hide, and now this."

The broader market held up a little better, five days before the Federal Reserve is expected to cut interest rates for a sixth time this year.

Optimism about lower rates lifted stocks on Wednesday and Thursday. But before that, a raft of negative corporate pre-announcements pushed shares lower. The tension left the major indexes flat on the week.

    
 

The Dow Jones industrial average fell 110.84 points, or 1 percent, to 10,604.59 Friday, while the S&P 500, heavy in drug stocks such as Schering-Plough, American Home Products and Pfizer, declined 11.69, or 0.94 percent, to 1,225.35.

The Nasdaq composite index shed 23.94 points, or 1.1 percent, to 2,034.82, breaking a three-session winning streak and narrowing its weekly gain to 0.3 percent.

News that the U.S. military moved to its highest state of alert in the Persian Gulf also put pressure on stocks. U.S. officials said the move was because of increased threats against American interests overseas.

For the week, the Dow fell 0.17 percent, while the S&P 500 inched 0.9 percent higher.

More stocks fell than rose. Declining issues on the New York Stock Exchange topped advancing ones 1,816 to 1,246 as 1.1 billion shares traded. Nasdaq losers topped winners 2,116 to 1,567 as 1.7 billion shares traded.

In other markets, Treasury securities rose. The dollar edged lower versus the euro and was flat against the yen.


Just say no

Merck warned it will miss second-quarter and full-year earnings forecasts, blaming weak sales of its arthritis drug Vioxx and the strong dollar, which can make it tougher for U.S. companies to sell products overseas.

Other drug makers also fell, including Pfizer (PFE: down $2.08 to $42.79, Research, Estimates) and Dow component Johnson & Johnson (JNJ: down $0.63 to $52.39, Research, Estimates).

But Jack Baker, head of equities at Putnam Lovell Securities, said that declines in Merck (MRK: down $6.67 to $67.80, Research, Estimates) often are good times to buy.

    
 

"If you are not in the stock, I'd start picking away at it," he told CNNfn's Market Call.

Schering-Plough (SGP: down $2.65 to $37.90, Research, Estimates), meanwhile, said the Food and Drug Administration found more problems at its plants, possibly delaying its successor to its allergy drug Claritin.

 
Merck's disappointment stands out among other high-profile corporate warnings, which have been concentrated in technology companies.

Among the latest, Symantec (SYMC: down $22.41 to $38.90, Research, Estimates), a software maker, said its first-quarter sales would fall short of expectations.

Concord Camera (LENS: down $1.80 to $6.02, Research, Estimates), which makes disposable cameras, said it will lose money in its fourth quarter. The company earlier forecast a profit.

Footwear and handbag maker Kenneth Cole (KCP: down $4.56 to $19.14, Research, Estimates) said second-quarter earnings will come in about half of what analysts expected.

Still, shares of Micron Technology (MU: up $0.67 to $38.38, Research, Estimates) rose even after the chipmaker posted a loss in the latest quarter that was much wider than expected.

"A lot of what appears to be bad news has been discounted by stocks," Bill Burke, director of sales trading at Robertson Stephens, told CNNfn's The Money Gang.

JDS Uniphase (JDSU: up $0.85 to $11.76, Research, Estimates), which makes fiber optic equipment, rallied. Wit SoundView upgraded JDS Uniphase to "strong buy" from "buy." Analysts there said the stock could double over the next twelve months as fiber-optic spending improves.

    
 

The Dow's biggest gainer, IBM (IBM: up $0.27 to $112.87, Research, Estimates), recouped some of its losses from earlier this week.

Other tech stocks moving higher include Sun Microsystems (SUNW: up $0.14 to $14.47, Research, Estimates) and Nortel Networks (NT: up $0.30 to $8.75, Research, Estimates), two companies that issuing warnings in recent weeks.

Anticipation that the Federal Reserve will cut interest rates next week has supported stocks. Economists expect at least a quarter-percentage point rate cut when the central bank ends a two-day meeting Wednesday.

Mark Boutote, managing director of Direct Brokerage, says traders at the New York Stock Exchange are betting on a larger, half-percentage-point cut.

"That seems to be the talk on the floor now of 50 basis points, instead of 25," Boutote told CNNfn's Market Call.

The Fed, concerned about the economy's slowdown, lowered borrowing costs five times this year.

The market this week has been turbulent as hopes for an economic turnaround clashed with the latest round of bad news on corporate profits. On the one hand, figures on leading economic indicators and first-time claims for jobless benefits signaled stability.

But warnings from companies such as Transmeta, a maker of microprocessors, and Tellabs, a telecom equipment maker, reminded investors that companies are having a tough time selling their products and services.

The major stock indexes reflect this. The S&P 500, among the broadest of indexes, is down 7.2 percent this year and is off 19.7 percent from its peak of last year. 

Copyright ? 2001 CNN America, Inc.
An AOL Time Warner Company
ALL RIGHTS RESERVED.
Terms under which this service is provided to you.
privacy policy